A clinical trial status update for abaloparatide was recorded on September 28, 2026. The study, registered as NCT03841058, is titled "Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery."
The trial is a Phase 2 study. Its current status is listed as active, not recruiting, meaning enrollment has closed but the study is ongoing.
The trial compares abaloparatide to placebo in post-menopausal women undergoing initial spinal fusion surgery, and also includes men receiving abaloparatide in the same surgical context. No results have been posted for this study as of this update.
Abaloparatide is an approved compound. This record reflects only a change in trial status and does not represent new efficacy or safety findings. Readers should not interpret this update as indicating any outcome of the research.
Further details about the trial design, phase, and status can be found in the official registry listing. For more background on abaloparatide itself, readers can consult the compound overview.